<DOC>
	<DOC>NCT00657007</DOC>
	<brief_summary>The purpose of thie study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of belimumab (LymphoStat-B™)in subjects with SLE.</brief_summary>
	<brief_title>Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis of SLE by ACR criteria Stable SLE disease activity On stable SLE treatment regimen History of measurable autoantibodies Key Pregnant or nursing Received a nonFDA approved investigational agent within last 28 days Received cyclosporin, intravenous immunoglobulin (IVIG) or plasmapheresis within last 6 months Active lupus nephritis requiring hemodialysis, intravenous cyclophosphamide (Cytoxan™), or highdose prednisone (&gt; 100 mg/day) within last 6 months Active central nervous system (CNS) lupus requiring medical intervention within last 6 months History of renal transplant History of clinical evidence of an active significant acute or chronic diseases Have required management or hospitalization of any infection within last 4 weeks. History of hypogammaglobulinemia or IgA deficiency Have current drug or alcohol addiction History of or test positive at screening for HIV, Hepatitis B or Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>lupus</keyword>
	<keyword>SLE</keyword>
</DOC>